Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum chemotherapy + paclitaxel + bevacizumab ± atezolizumab in metastatic, persistent, or recurrent cervical carcinoma
2018-000367-83Phase 3Active
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Overall Survival. Started Jun 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-000367-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000367-83.